Islamabad — The Ministry of National Health Services and the Drug Regulatory Authority of Pakistan (DRAP) have kicked off a concerted effort to tackle the Hepatitis Delta Virus (HDV), a silent but severe threat that worsens liver damage in those already battling Hepatitis B.
Federal Minister Syed Mustafa Kamal recently chaired a high-level meeting with representatives from China’s Huahui Health and IQVIA Pakistan to map out a strategic response. With estimates pointing to over one million Pakistanis living with HDV — and roughly 20 percent of Hepatitis B patients potentially co-infected — the stakes are high: untreated cases often race toward cirrhosis, liver failure, or cancer, leaving families desperate and the health system stretched.
چین کی معروف ہیلتھ کمپنی ہواہوئی ہیلتھ کے سی ای او مسٹر بن چن نے وفاقی وزیر برائے قومی صحت سید مصطفیٰ کمال کو ہیپاٹائٹس ڈیلٹا کے لیے ایمرجنسی ایکسس، جدید علاجی سہولیات اور قومی سطح پر اشتراکِ عمل سے متعلق جامع پریزنٹیشن دی۔#MustafaKamal #HealthMinister #HepatitisDelta… pic.twitter.com/O0vq0HoY3e
— Syed Mustafa Kamal (@KamalMQM) January 30, 2026
Key Highlights
- Over one million people in Pakistan estimated to have HDV, a satellite virus that only infects those with Hepatitis B (HBV).
- About 20 percent of HBV patients may carry HDV co-infection, but routine testing remains limited, allowing many cases to go undetected.
- HDV drives faster progression to severe liver complications like cirrhosis and hepatocellular carcinoma compared to HBV alone.
- Huahui Health presented updates on its investigational therapy Libevitug (HH-003), a first-in-class monoclonal antibody that recently wrapped successful Phase 2 trials across multiple countries.
- The drug has secured conditional approval in China and Breakthrough Therapy Designation from both China’s NMPA and the U.S. FDA, signaling strong potential for better outcomes.
- Government commits to facilitating Phase 3 trials in Pakistan, plus technology transfer for local manufacturing through a partnership with a top domestic pharma firm — aiming for affordable, home-grown access.
- DRAP CEO Dr. Obaidullah Malik stressed transparent, science-driven approvals to ensure safety while speeding up life-saving innovations.
Meeting Spotlights Urgent Clinical Burden and Diagnostic Gaps
The minister didn’t mince words about the toll: HDV turns an already tough Hepatitis B infection into something far more aggressive. Patients often face fatigue, jaundice, swelling, and eventually no choice but a transplant — a harsh reality for too many families across the country.
Data shared at the session painted a stark picture — that 20 percent co-infection figure among HBV cases highlights how under-testing lets the virus slip through the cracks. For everyday Pakistanis, especially in rural or low-resource areas, delayed diagnosis means lost time and worsening health.
Huahui Health outlined promising results from Libevitug: in trials, it showed solid antiviral effects, ALT normalization, and good tolerability — offering hope where options have been scarce.
What’s Next for HDV Patients in Pakistan
The real game-changer here is the push for local production and Phase 3 trials under DRAP oversight. By partnering with a leading Pakistani manufacturer, the government aims to bring advanced biological treatments within reach — cutting costs, building self-reliance, and strengthening national health security.
You May Like To Read: NA Committee Flags Alarming HIV Surge and Regulatory Lapses
This initiative reflects Pakistan’s proactive stance on emerging health threats: bridging global expertise with local capacity to protect lives and ease the burden on families facing liver disease. If rolled out smoothly, it could mark a turning point in how we handle this hidden epidemic.
Check out our latest video:
